StockNews.com began coverage on shares of Surmodics (NASDAQ:SRDX - Free Report) in a report released on Thursday morning. The brokerage issued a hold rating on the stock.
Separately, Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research report on Monday, August 5th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $50.00.
View Our Latest Research Report on Surmodics
Surmodics Price Performance
Shares of SRDX traded down $0.09 during midday trading on Thursday, hitting $38.40. The company's stock had a trading volume of 272,138 shares, compared to its average volume of 230,832. Surmodics has a one year low of $25.17 and a one year high of $42.44. The company's fifty day simple moving average is $38.62 and its two-hundred day simple moving average is $38.60. The company has a quick ratio of 3.22, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $547.85 million, a price-to-earnings ratio of -384.90 and a beta of 1.20.
Institutional Investors Weigh In On Surmodics
Institutional investors have recently made changes to their positions in the stock. Quest Partners LLC grew its position in shares of Surmodics by 107,100.0% in the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company's stock valued at $42,000 after buying an additional 1,071 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Surmodics by 14.7% in the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company's stock valued at $151,000 after purchasing an additional 660 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company's stock valued at $166,000 after purchasing an additional 673 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Surmodics by 7.5% in the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company's stock valued at $202,000 after purchasing an additional 481 shares during the period. Finally, Hardin Capital Partners LLC acquired a new position in shares of Surmodics in the 2nd quarter valued at about $206,000. Institutional investors own 96.63% of the company's stock.
Surmodics Company Profile
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
